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We examined national trends and socioeconomic inequalities in cancer survival in England and Wales during the 1990s, using
population-based data on 2.2 million patients who were diagnosed with one of the 20 most common cancers between 1986 and
1999 and followed up to 2001. Patients were assigned to one of five deprivation categories (from ‘affluent’ to ‘deprived’) using
characteristics of their electoral ward of residence at diagnosis. We estimated relative survival up to 5 years after diagnosis, adjusting
separately in each deprivation category for background mortality by age, sex and calendar period. We estimated trends in survival and
in the difference in survival between deprivation categories (‘deprivation gap’) over the periods 1986–90, 1991–95 and 1996–99.
We used period analysis to examine likely survival rates in the near future. Survival improved for most cancers in both sexes during
the 1990s, and appears likely to continue improving for most cancers in the near future. The deprivation gap in survival between rich
and poor was wider for patients diagnosed in the late 1990s than in the late 1980s. Increases in cancer survival in England and Wales
during the 1990s are shown to be significantly associated with a widening deprivation gap in survival.
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Cancer survival in England and Wales depends on socioeconomic
status. Among adults living in the most deprived areas who were
diagnosed during 1981–90, 5-year survival was significantly lower
than for those in the most affluent areas for 44 of 47 different
cancers (Coleman et al, 1999).
Strategic changes in cancer management from 1995 were
designed to improve cancer outcomes and the equality of access
to optimal cancer care (Expert Advisory Group on Cancer, 1995).
Government policy to reduce delays in diagnosis and treatment
(NHS Executive, 1997) would also be expected to lead to higher
survival rates in due course (Stockton et al, 1997; Richards et al,
1999).
We have examined national trends and socioeconomic inequal-
ities in cancer survival in England and Wales for patients
diagnosed up to 1999 and followed up to 31 December 2001.
MATERIALS AND METHODS
We examined the data for some 2.2 million patients diagnosed
aged 15–99 years with one of the 20 most common cancers
between 1 January 1986 and 31 December 1999 in England and
Wales (Table 1). Anonymised data were obtained from the Office
for National Statistics, after linkage of incident cases in the
National Cancer Registry with information on deaths from the
NHS Central Register (Office for National Statistics, 2003a). The
data were extracted for analysis on 5 November 2002, when the
vital status (alive, emigrated, dead, not traced) at 31 December
2001 was known for 98.4% of patients. (The survival of 2887690
adults diagnosed 1971–90 and followed up to 1995 was reported in
1999 (Coleman et al, 1999). In late 2002, we sought the last known
vital status up to 31 December 2001 for the 448598 patients not
known to have died by 31 December 1995. The National Cancer
Registry is continuously updated, and in the 5 years since data
were extracted for the previous analyses in July 1997, the regional
cancer registries had requested deletion of 4196 records: 2206 cases
in which the diagnosis of cancer had been revoked were excluded,
but the corrected tumour record was used for 1990 cases that had
been resubmitted after correction of errors in the original data,
often with a revised date of birth or diagnosis. Consequently, the
number of cases included and the survival estimates for patients
diagnosed 1986–90 may differ slightly from those published
previously.) Ten percent of patients were excluded because their
recorded survival time was zero (mainly death certificate only
(DCO) cases whose survival time was unknown) (Table 1). Other
patients were excluded because it was not their first cancer (3.2%)
or for other reasons (2.3%) including unknown vital status.
Each patient was assigned to one of five categories of
socioeconomic deprivation based on their electoral ward of
residence at diagnosis, the smallest geographic unit for which
adequate data were available over the entire period 1986–99.
Deprivation categories were labelled from least deprived (affluent,
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yor ‘rich’) to most deprived (‘poor’). For patients diagnosed during
1986–95, the categories were based on quintiles of the national
distribution of the ward Carstairs score (Carstairs, 1995) derived
from the 1991 Census. For patients diagnosed during 1996–99,
deprivation categories were based on quintiles of the ward income
domain score, a subcomponent of the indices of multiple
deprivation (IMD) 2000 for England (Department of the Environ-
ment Transport and the Regions, 2000), combined with the
comparable but not precisely equivalent index available for Wales
(National Assembly for Wales, 2000).
Complete life tables by single year of age (up to 99 years), sex
and deprivation category were derived from the numbers of deaths
in each ward in England and Wales for the periods 1990–92 and
1997–99. Population denominators for the 1990–92 life tables
were derived from the 1991 census (Office for National Statistics,
1991). For 1997–99, the age–sex structure of each Local Authority
in the 2001 Census (Office for National Statistics, 2003b) was
applied to the estimated population counts in 1998 (Penhale and
Noble, 2000) for each of its constituent wards (Woods et al.,
submitted for publication).
We estimated national relative survival rates for England and
Wales for each cancer and each sex, by age, deprivation category
and calendar period of diagnosis. Relative survival is the ratio of
the observed (absolute) survival of the cancer patients and the
survival that would have been expected if the patients had had the
same age- and sex-specific mortality in each period (background
mortality) as the general population (Berkson and Gage, 1950).
The 1990–92 life tables were used to represent background
mortality by age, sex and deprivation category during 1986–95,
and the 1997–99 life tables for the period 1996–2001. Survival
probabilities for most cancers were estimated at monthly intervals
for the first 6 months, then 3-monthly up to 1 year and 6-monthly
from 1 to 5 years. Survival for patients diagnosed during 1986–90
was used as the baseline for estimating trends in both national
survival rates and deprivation gradients in survival. Cumulative
relative survival up to 5 years after diagnosis was estimated
separately for patients diagnosed in the calendar periods 1986–90,
1991–95 and 1996–99. For the first two periods, data on at least 5
years of follow-up were available for all patients, and classical
cohort analysis of survival was used. For the period 1996–99, 5
years’ potential follow-up was only available for those diagnosed in
1996, but the most up-to-date estimates for shorter-term survival
probabilities were used for patients diagnosed in later years
(complete analysis).
We applied the maximum-likelihood approach for individual
records (Este `ve et al, 1990) to estimate observed and relative
survival, using the algorithm developed for previous analyses
(Coleman et al, 1999), modified to enable period analysis (Brenner
and Gefeller, 1996). Period analysis is a recent methodological
development that enables predictions of, say, 5-year survival to be
made for patients who were diagnosed less than 5 years ago; this is
analogous to the prediction of life expectancy at birth in a given
year from the death rates at all ages observed during that year. We
used this approach for the period 2000–01. For this purpose, we
estimated the conditional probabilities of relative survival up to 5
years after diagnosis from the survival experience during 2000–01
of cancer patients diagnosed during 1996–99.
Survival gradients across the five categories of deprivation were
estimated with linear regression, weighted by the variance of the
relative survival estimate (Grizzle et al, 1969), using STATA
software (StataCorp, 1997). The difference between the relative
survival rates fitted by the regression model for the most affluent
and most deprived categories is described as the ‘deprivation gap’
in survival. The deprivation gap is reported as negative if survival
was lower in the poor than the rich. Changes in deprivation
gradient between successive calendar periods, adjusted for secular
trends in survival, were estimated from the interaction between
calendar period and deprivation. We report the average change in
the deprivation gap every 5 years, taking account of the shorter
final period (4 years). We also report the temporal change in
survival every 5 years, adjusted for change in the deprivation gap.
The relationship between trends in 1- and 5-year survival during
the 1990s and concurrent trends in the deprivation gap in survival
was also examined, using linear regression weighted by the
conditional variance of the change in deprivation gap given the
change in survival. The regression was carried out separately for
men (16 cancers) and women (17 cancers).
RESULTS
Cancer survival improved steadily for most cancers in both sexes
up to 2001. The survival curves for rectal cancer in men diagnosed
in successive calendar periods up to 1999 are shown as an example
(Figure 1): the period curve, based on survival experienced during
2000–01, suggests the improvement is still continuing. Five year
survival increased for 15 of the 16 cancers examined among men
diagnosed in England and Wales over the period 1986–99, and the
average increase every 5 years during the 1990s was statistically
significant for 11 of these, but not for cancers of the pancreas, lung,
testis or bladder (Table 2). Brain tumour survival fell significantly.
For women, survival increased for 13 of the 17 cancers examined,
and the average increase every 5 years was significant for nine of
these, but not for lung, melanoma, cervix or leukaemia. For
cancers of the oesophagus, bladder or brain, survival was no better
for women diagnosed in 1996–99 than for those diagnosed in
1986–90, and survival was significantly lower for pancreatic
cancer.
Survival for patients living in the poorest one-fifth of electoral
wards of England and Wales when diagnosed during 1996–99 was
lower than for those in the richest fifth of wards for 28 of the 33
Table 1 Cancer patients diagnosed in England and Wales, 1986–99:
exclusions (% of those eligible) and number (%) of eligible cases included in
survival analysis
Malignancy
Zero
survival
a
Multiple
primary
b Other
c
Analysed
no. %
Oesophagus 10.8 3.6 1.7 65591 83.9
Stomach 14.2 3.0 2.0 112367 80.8
Colon 11.5 3.5 2.4 206879 82.6
Rectum 6.6 3.4 2.2 132602 87.8
Pancreas 22.0 2.8 1.7 62815 73.6
Larynx 4.3 3.8 2.8 20112 89.2
Lung 16.0 3.2 2.0 391678 78.8
Melanoma 2.8 3.0 2.7 55394 91.5
Breast (F) 6.1 2.4 3.1 382277 88.5
Cervix 3.9 3.1 3.1 44090 89.9
Uterus 5.7 5.2 2.2 53092 87.0
Ovary 10.2 3.6 2.0 63833 84.2
Prostate 8.5 3.3 1.9 201134 86.3
Testis 0.9 0.9 2.8 18605 95.4
Bladder 5.2 4.4 2.3 141531 88.1
Kidney 12.2 4.6 2.0 49721 81.3
Brain 9.8 1.8 2.5 37917 85.9
Non-Hodgkin
lymphoma
9.0 3.2 2.3 78894 85.5
Myeloma 13.1 3.1 2.0 32419 81.9
Leukaemia 15.9 3.5 2.3 56914 78.3
Total 10.4 3.2 2.3 2207865 84.1
aDate of diagnosis same as date of death: some patients did die on the day of
diagnosis, but most were registered solely from death certificate, with unknown
survival time.
bPersons who had a previous primary malignancy.
cAged 100 years or
over at diagnosis, vital status or sex unknown, sex-site error, invalid dates, duplicate
registration or synchronous tumour.
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ycancer–sex combinations (Table 2). For 11 cancers in men and
nine in women, this deprivation gap in survival was statistically
significant.
For 12 of the 16 cancers examined in men, the deprivation gap in
survival between rich and poor was wider for those diagnosed
during 1996–99 than for those diagnosed during 1986–90. The
average increase every 5 years in the deprivation gap over that
period was itself statistically significant for cancers of the
oesophagus, colon, rectum, larynx and prostate, and for laryngeal
cancer the deprivation gap in survival reached 17% for men
diagnosed during 1996–99. By contrast, there was a significant
reduction in the deprivation gap for testicular and brain tumours.
For women, the deprivation gap in survival also increased
during the 1990s, but less markedly than for men. For nine of the
17 cancers examined, the deprivation gap was wider for women
diagnosed during 1996–99 than 1986–90. The average increase
every 5 years in the deprivation gap was significant for cancers of
the colon and rectum, and for myeloma. By contrast, there was a
significant reduction in the deprivation gap for melanoma of the
skin, and it also became slightly less marked for cancers of the
oesophagus, pancreas, ovary and kidney, and the leukaemias
(Table 2).
Five-year survival for lung cancer patients diagnosed during
1996–99 was 6% in men and women, not significantly better than
for patients diagnosed a decade or so earlier. Survival among men
was significantly lower for the poor than the rich (deprivation gap
 1.4%), a wider gap than for men diagnosed 1986–90, although
the 5-yearly increase in the gap was not itself significant. The
deprivation gap in survival for women diagnosed during 1996–99
was small, and unchanged from a decade earlier.
Breast cancer survival at 5 years in women diagnosed during
1996–99 was 80%, a rapid and significant average increase of 6.1%
every 5 years since 1986–90. The deprivation gap in survival was
 5.8% (95% CI  6.7 to  4.8%), no different to that for women
diagnosed during 1986–1990.
Prostate cancer survival at 5 years among men diagnosed during
1996–99 was 68%, a remarkable average increase, after adjustment
for deprivation, of 15.9% every 5 years (95% CI 14.8–17.0%) from
43% for men diagnosed during 1986–90. The deprivation gap in
survival steepened significantly by about  3% every 5 years during
the 1990s, reaching  7.2% for men diagnosed during 1996–99.
Five-year survival from colon cancer increased by about 6%
every 5 years in both sexes, to about 47–48%, and rectal cancer
survival rose by about 8% every 5 years, to 49% for men diagnosed
during 1996–99 (Figure 1) and 51% in women. The deprivation
gap in 5-year survival became significantly steeper during the
1990s for both cancers and in both sexes, reaching  6% to  7%
for colon cancer and  8% to  9% for rectal cancer (Figure 2).
For brain tumours, 5-year survival fell in both sexes to 12–14%
for those diagnosed 1996–99. For men, the average decline of 3.1%
every 5 years was statistically significant at the 1% level. This
anomalous trend was accompanied by a positive deprivation
gradient of borderline significance (2.6%; 95% CI  0.1% to
þ5.2%).
Improvements in 1- and 5-year survival for the 20 most common
cancers were significantly associated with an increase in the
deprivation gap in both sexes (Figure 3: each data point represents
a different cancer). The association is more marked for men, but
all four associations are statistically significant. Prostate cancer
was excluded from this analysis because of the outlying rate of
increase in 5-year survival (15.9% every 5 years), but the slope of
the regression was only marginally steeper as a result.
The results suggest that for the 16 cancers examined in men, an
increase of 5% in the national average 5-year survival rate during
the 1990s was typically associated with an increase of about 1.5%
in the deprivation gap in survival between rich and poor.
Period analysis
Survival estimates based on period analysis for 2000–01 are
slightly higher for most cancers than conventional survival
estimates for patients diagnosed during 1996–99 (Table 2). These
predictions generally confirm the improvements observed over the
period 1986–99.
DISCUSSION
Cancer survival improved during the 1990s for almost all the 20
common cancers examined here. Period survival estimates based
on events during 2000–01 were higher for most cancers than
conventional estimates for patients diagnosed during 1996–99,
suggesting that survival rates are likely to continue rising for the
next few years. For many cancers, however, survival improved
more for patients living in affluent wards than for those living in
deprived wards. As a result, the existing deprivation gap in
survival between rich and poor widened during the 1990s.
There were some notable exceptions to these patterns. Average
survival from brain tumours for both men and women fell slightly
but steadily during the 1990s. One possible explanation would be
greater use of cerebral CT or MRI imaging for affluent patients.
Cerebral tumours might then have been diagnosed more often in
affluent patients presenting with rapidly fatal intracranial events
that might previously have been diagnosed (and certified without
post-mortem) as a cerebrovascular accident. This explanation is
supported by the fact that incidence in the most affluent group
rose more than in deprived groups between 1986 and 1999, and
survival in the first 6 months after diagnosis fell more (data not
shown).
The reduction in the deprivation gradient for testicular cancer
survival suggests a ceiling effect, since the national average 5-year
survival estimate for men diagnosed during 1996–99 was 96%, and
any further increase in survival would be expected to affect men in
the less affluent groups, whose survival had been lower. The
reduction in the deprivation gap for women with melanoma
(national average 5-year survival 89%) may have a similar
explanation.
The extraordinary deprivation gap in survival for men
diagnosed with laryngeal cancer during 1996–99 was significantly
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Figure 1 Relative survival up to 5 years, by calendar period of diagnosis,
England and Wales, men with cancer of the rectum diagnosed 1986–99
and followed up to 2001. The dashed curve is derived from period analysis
using survival experience during 2000–01.
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yTable 2 Five-year relative survival (%) and deprivation gap in survival, cancer patients diagnosed in England and Wales 1996–99, with average change
every 5 years during 1986–99, and period estimate of 5-year survival (%), using events during 2000–01
5-year relative survival (%) Deprivation gap (%) in 5-year survival
a
5-year survival (%)
Patients diagnosed 1996–99
Average change every
5 years
b
Patients diagnosed
1996–99
Average change every
5 years
c
(period estimate,
events in 2000–01)
d
Malignancy No. Survival (%) (95% CI) % (95% CI) Gap (%) (95% CI) % (95% CI) % (95% CI)
Oesophagus
Men 12814 7.6 (7.0, 8.2) 1.7** (0.6, 2.8)  1.9* ( 3.8,  0.1)  1.4* ( 2.6,  0.1) 7.9 (6.9, 9.0)
Women 8219 7.2 (6.5, 8.0)  0.3 ( 1.7, 1.0)  0.2 ( 2.4, 2.0) 0.3 ( 1.2, 1.8) 7.7 (6.5, 9.1)
Stomach
Men 19555 12.9 (12.3, 13.5) 2.0** (0.9, 3.1)  1.7 ( 3.6, 0.1)  0.8 ( 1.9, 0.3) 14.7 (13.3, 16.1)
Women 10618 14.0 (13.2, 14.9) 1.7* (0.3, 3.2) 1.7 ( 0.9, 4.3)  0.5 ( 2.0, 1.1) 18.0 (15.8, 20.2)
Colon
Men 31977 47.6 (46.8, 48.3) 5.6** (4.2, 7.0)  5.7** ( 8.0,  3.4)  1.9* ( 3.4,  0.3) 51.7 (49.9, 53.5)
Women 32243 47.4 (46.7, 48.1) 5.6** (4.3, 6.8)  7.3** ( 9.4,  5.1)  2.2** ( 3.6,  0.8) 52.7 (50.7, 54.6)
Rectum
Men 24702 48.7 (47.8, 49.6) 7.4** (5.8, 8.9)  9.4** ( 12.0,  6.8)  2.4** ( 4.1,  0.6) 50.6 (48.7, 52.5)
Women 17264 51.3 (50.3, 52.4) 8.1** (6.3, 10.0)  8.3** ( 11.4,  5.2)  2.5* ( 4.5,  0.5) 51.9 (49.4, 54.3)
Pancreas
Men 8837 2.7 (2.3, 3.1) 0.1 ( 0.6, 0.9)  0.9 ( 2.2, 0.4)  0.6 ( 1.5, 0.3) 2.4 (1.8, 3.1)
Women 9082 2.3 (1.9, 2.7)  0.8* ( 1.4,  0.1) 1.1* (0.1, 2.1) 0.7 (0.0, 1.4) 2.2 (1.7, 2.9)
Larynx
Men 5666 64.3 (62.5, 66.1) 3.3* (0.0, 6.7)  17.2** ( 22.4,  11.9)  3.7* ( 7.1,  0.2) 64.7 (60.6, 68.5)
Lung
Men 67862 6.0 (5.8, 6.3) 0.1 ( 0.3, 0.5)  1.4** ( 2.2,  0.7)  0.3 ( 0.7, 0.2) 6.5 (6.1, 7.0)
Women 39455 6.5 (6.2, 6.8) 0.1 ( 0.5, 0.7)  0.6 ( 1.6, 0.3) 0.0 ( 0.6, 0.7) 7.3 (6.6, 7.9)
Melanoma of skin
Men 7983 77.9 (76.5, 79.2) 4.0** (1.6, 6.3)  6.2** ( 10.2,  2.3)  0.4 ( 3.3, 2.6) 78.6 (76.0, 80.9)
Women 10831 89.5 (88.6, 90.3) 0.3 ( 1.2, 1.8)  0.9 ( 3.4, 1.6) 2.6** (0.7, 4.4) 91.2 (89.3, 92.8)
Breast
Women 125093 79.8 (79.5, 80.1) 6.1** (5.5, 6.7)  5.8** ( 6.7,  4.8)  0.1 ( 0.8, 0.6) 81.4 (80.8, 82.0)
Cervix
Women 10344 65.5 (64.4, 66.6) 0.9 ( 1.1, 2.8)  5.1** ( 8.4,  1.7)  0.4 ( 2.4, 1.6) 65.7 (62.9, 68.4)
Uterus
Women 16549 75.8 (74.8, 76.7) 2.5** (0.9, 4.1)  4.2** ( 6.9,  1.6)  0.8 ( 2.7, 1.1) 77.1 (75.0, 79.1)
Ovary
Women 20177 38.1 (37.3, 38.9) 2.9** (1.5, 4.3) 1.0 ( 1.4, 3.5) 1.4 ( 0.2, 3.0) 41.3 (39.3, 43.4)
Prostate
Men 73921 68.4 (67.7, 69.0) 15.9** (14.8, 17.0)  7.2** ( 9.0,  5.5)  3.2** ( 4.5,  2.0) 71.1 (70.0, 72.2)
Testis
Men 6153 96.5 (95.9, 97.0) 1.2 ( 0.2, 2.5)  1.3 ( 3.3, 0.8) 1.8* (0.2, 3.4) 97.9 (96.9, 98.5)
Bladder
Men 29252 66.5 (65.6, 67.4) 0.7 ( 0.7, 2.2)  5.7** ( 8.2,  3.1)  0.9 ( 2.5, 0.8) 66.0 (64.0, 68.0)
Women 11345 56.3 (55.0, 57.6)  0.8 ( 3.0, 1.5)  5.8** ( 9.5,  2.0)  0.7 ( 3.2, 1.8) 56.8 (53.4, 60.1)
Kidney
Men 10391 46.1 (44.8, 47.4) 4.5** (2.1, 6.8)  5.8** ( 9.5,  2.0)  1.7 ( 4.3, 0.9) 49.7 (46.4, 52.9)
Women 6191 45.7 (44.1, 47.3) 3.7* (0.8, 6.7) 0.0 ( 4.6, 4.6) 1.6 ( 1.6, 4.8) 49.0 (44.4, 53.4)
Brain
Men 6950 11.6 (10.7, 12.5)  3.1** ( 4.7,  1.4) 2.6 ( 0.1, 5.2) 2.5** (0.6, 4.4) 11.3 (9.6, 13.2)
Women 5011 14.0 (12.9, 15.1)  0.8 ( 2.9, 1.2)  1.4 ( 4.6, 1.9)  0.3 ( 2.6, 2.0) 16.4 (13.6, 19.4)
Non-Hodgkin Lymphoma
Men 13952 51.3 (50.2, 52.4) 4.0** (2.0, 5.9)  7.3** ( 10.4,  4.1)  1.5 ( 3.8, 0.7) 54.5 (51.7, 57.3)
Women 12281 52.7 (51.5, 53.9) 3.6** (1.4, 5.8)  5.4** ( 8.9,  1.9)  0.4 ( 2.8, 2.1) 55.9 (52.8, 58.8)
Myeloma
Men 5300 25.6 (23.8, 27.4) 4.4** (1.6, 7.3)  4.8 ( 10.0, 0.4)  2.8 ( 6.1, 0.4) 27.5 (24.1, 31.1)
Women 4754 23.8 (22.0, 25.6) 5.8** (3.0, 8.7)  7.7** ( 12.9,  2.6)  5.6** ( 8.8,  2.4) 25.8 (22.4, 29.3)
Leukaemia
Men 9966 39.7 (38.4, 41.0) 4.7** (2.4, 7.0)  4.4* ( 8.3,  0.5) 0.0 ( 2.5, 2.6) 42.7 (39.3, 46.0)
Women 7715 35.9 (34.4, 37.3) 1.7 ( 0.8, 4.2)  2.5 ( 6.7, 1.6) 1.8 ( 0.9, 4.6) 39.4 (35.6, 43.1)
* Statistically significant at 5%; **statistically significant at 1%.
aAverage change in 5-year relative survival every 5 years over the period 1986–99, adjusted for deprivation (see
text).
bFitted difference in relative survival between most affluent and most deprived quintiles.
cAverage change in deprivation gap every 5 years over the period 1986–99,
adjusted for changes in survival over time (see text).
dRelative survival for patients diagnosed 1996–99 and alive during all or part of 2000–01 (see text).
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decades (Coleman et al, 1999), yet there is no evidence of
differential trends in incidence between socioeconomic groups that
might have suggested drift in the type of malignancy being
recorded (data not shown).
Survival from cancers of the rectum and colon increased more
rapidly during the 1990s in both sexes than during the 1970s or the
1980s (Coleman et al, 1999). These trends are consistent with the
continuing decline in mortality and the steady rise in incidence
(Quinn et al, 2001). The increase in survival may be attributable to
improvements in surgery (McArdle and Hole, 2002) and reduction
in operative mortality (Mitry et al, 2002). Taken together, these
trends suggest that improvements in survival may be attributable
both to earlier diagnosis and to improved treatment. Improve-
ments in survival were notably faster for the more affluent groups
in both sexes, however: the deprivation gap in 5-year survival for
rectal cancer increased significantly to 8% for patients diagnosed
1996–99 and 6% for colon cancer. Adverse prognostic factors such
as proximal subsite and mucin-producing adenocarcinoma are not
more common in lower socioeconomic groups (Lyratzopoulos
et al, 2003), and differences in stage at diagnosis do not appear to
explain the survival gradient (Schrijvers et al, 1995). This suggests
that the most deprived patients may not have benefited equally
from advances in early diagnosis and treatment. Incidence trends
for rectal cancer during the 1990s were similar for all deprivation
groups, but the overall increase in colon cancer was smaller in the
least affluent group (data not shown): colonoscopic polypectomy
may be less accessible to the least affluent patients, but it is unclear
if that alone could account for the differences in incidence, and
only invasive malignant tumours were included in this study. A
large study of colorectal cancer patients hospitalised in the US
Veteran Administration health care system during the period
1987–98 did not show the survival differences between black and
white patients consistently reported from the SEER program of
population-based registries. The authors suggest that this may be
attributable to the VA being an equal access system, without
financial and health insurance barriers to care (Rabeneck et al,
2003).
The extremely rapid increase in prostate cancer survival reflects
the increase in diagnosis and treatment of asymptomatic prostatic
cancers as a result of increasingly widespread use of prostate-
specific antigen (PSA) tests during the 1990s (Evans and Mller,
2003). Many of these tumours would never have been diagnosed in
life, and PSA testing has led to a rapid increase in recorded
incidence and survival rates in many countries (Coleman et al,
2003). The trend in prostate cancer survival in the population is
not an artefact, however: it simply reflects the rapid shift in the
biological and clinical spectrum of prostate tumours that are now
being diagnosed as a result of new diagnostic techniques such as
PSA. The concurrent widening of the deprivation gap in survival
suggests that access to PSA tests has been more widespread among
men in affluent groups than in deprived groups. It is open to
question whether the trend in survival during the 1990s represents
an improvement for individual men with very early prostate
cancer.
Bias and artefact
It is unlikely that the observed patterns or trends in the
deprivation gap in survival between rich and poor can be
explained by bias or methodological factors. The gradients for
patients diagnosed during 1996–99 are flatter than if we had not
taken account of the widening socioeconomic gradient in back-
ground mortality (Department of Health, 1999) by constructing
separate deprivation-specific life tables for both the early and the
late 1990s (Coleman et al, 1999). Increases in deprivation gradient
during the 1990s are therefore smaller than they would have been
without this adjustment.
Exclusion from the analyses of patients whose duration of
survival was unknown (DCO cases) cannot explain the deprivation
gradients, because for each cancer the proportion of DCOs was
very similar in all deprivation groups (data not shown).
Selective failure to register cancer patients who survive longer
than average would produce lower survival (and incidence) rates,
but for such a bias to give rise to artefactual deprivation gradients
in survival, it would have to affect the poor more than the rich. We
simulated the impact on national survival estimates of all the
cancer registries in England and Wales having selectively failed to
register up to 30% of longer-term survivors in the most deprived
group, with lower proportions in intermediate groups and
assuming complete registration in the most affluent group. For
most cancers, such selective under-registration would have to
exceed 30% in order to account for the observed survival gradients
(data not shown). This is not likely. The absence of any
deprivation gradient in DCOs makes it an even less plausible
explanation, since DCOs also reflect inefficiency in the registration
of cancer patients during life (Jensen et al, 1991).
Full cohort estimates of survival for patients diagnosed in 1996,
for whom at least 5 years’ follow-up were available, were very
similar to estimates using all the available data for patients
diagnosed 1996–99 (complete analysis).
Public health implications
In 1995, an Expert Advisory Group on Cancer to the Chief Medical
Officers in England and Wales noted regional disparities in cancer
survival, and recommended the reorganisation of cancer treatment
services to ensure that all patients had access to ‘a uniformly high
quality of care ... wherever they may live, to ensure the maximum
possible cure rates and best quality of life’ (Calman-Hine report)
(Expert Advisory Group on Cancer, 1995). In December 2001,
however, the National Confidential Enquiry on Perioperative
Deaths (NCEPOD) reported wide variation in hospital caseloads
and experience, inadequate staging by clinicians, insufficient
reporting of stage by pathologists and poor compliance with
treatment guidelines for cancer patients operated as recently as
1999–2000 (NCEPOD, 2001).
Our analyses confirm that cancer survival in England and Wales
improved significantly during the 1990s. They also show that
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Figure 2 Five year relative survival (%) by deprivation category and
calendar period of diagnosis, England and Wales, men with cancer of the
rectum diagnosed in successive calendar periods 1986–99 and followed up
to 2001.
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affluent areas than those in deprived areas, even after correction
for the widening differences in overall mortality between rich and
poor. The results show a link between these trends, for the first
time to our knowledge. For the 20 most common cancers in
England and Wales, overall increases in survival during the 1990s
were significantly associated with a widening deprivation gap in
survival. Breast cancer and melanoma in women, and testicular
cancer in men were important exceptions to this pattern.
Such observations suggest the influence of delay or less effective
access to diagnosis and treatment for patients living in more
deprived areas. Lower socioeconomic groups tend to use NHS
services less in relation to need: this may reflect barriers to access
such as transport or time constraints, and differences in knowledge
or beliefs about the need for medical attention, but patients from
higher socioeconomic groups may also communicate more
effectively with the medical profession to obtain health care
(Dixon et al, 2003).
The NHS Cancer Plan, published in September 2000, aims to
reduce inequalities in cancer survival between rich and poor
(Department of Health, 2000), and the government has set
challenging targets for the NHS to reduce health inequalities
(Department of Health, 2003a).
Cancer patients diagnosed in 2000 or later could not be included
in these analyses, although period estimates suggest some
continuing improvement in survival. Up-to-date evidence on
survival by socioeconomic group will soon be needed to evaluate
whether the NHS Cancer Plan has helped to improve cancer
survival and to reduce inequalities in survival (Department of
Health, 2003b). The results published here underline the
importance of the NHS Cancer Plan being made to work.
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Figure 3 Average change every 5 years in relative survival (%) and in the deprivation gap in survival (%): England and Wales, 1- and 5-year survival,
selected cancers, men and women diagnosed during the period 1986–99 and followed up to 2001. Prostate cancer was excluded from the regression and
the scatter-plot (see text).
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